The management of type 2 diabetes with fixed ‐ratio combination insulin degludec/liraglutide (IDegLira) versus basal‐bolus therapy (insulin glargine U100 plus insulin aspart): A short‐term cost‐effectiveness analysis in the UK setting

Diabetes, Obesity and Metabolism, EarlyView.

Source: Diabetes, Obesity and Metabolism - June 25, 2018 Category: Endocrinology Authors: Russell Drummond MD , Samuel Malkin BSc , Michelle Du Preez BSc , Xin Ying Lee MSc , Barnaby Hunt MSc Source Type: research